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SUMMARY
A 15-year-old boy with a medical background of obesity, 
familial hyperlipidemia and acute recurrent pancreatitis, 
presented to emergency department reporting a 3-day 
course of periumbilical abdominal pain and nausea. 
Pain was noticed on epigastric palpation. Laboratory 
evaluation revealed leucocytosis, neutrophilia and 
pancreatic enzymes elevation more than three times 
the upper limit of normal. An acute recurrence of 
pancreatitis was diagnosed, was admitted to the 
hospital, being discharged after 5 days. Four days after, 
he was readmitted because of symptoms recurrence. 
Elevation of transaminases, GGT and direct bilirubin 
were noticed. Pancreatic enzymes still elevated but 
lower than in the previous episode. An endoscopic 
ultrasound revealed a Wirsung with a cephalic stricture 
and diffuse structural abnormalities suggestive of 
chronic pancreatitis. The patients was submitted to 
endotherapy with several sessions of endoscopic 
retrograde cholangiopancreatography including stenting 
and pancreatoscopy with marked clinical and imaging 
improvement. A genetic variant was identified.
BACkgRoUnd
Although chronic pancreatitis (CP) is a rare disease 
in children and adolescents, it has an important 
disease burden and a negative impact in quality of 
life. Given the rarity of the diagnosis, all cases of 
CP in paediatric age represent learning opportuni-
ties. This case shows the importance of a multidis-
ciplinary team in the management of patients with 
CP to ensure optimal outcomes and reinforces the 
value of a genetic analyses when no other cause is 
found for the disease.
CASe pReSenTATion
A 15-year-old adolescent boy presented to a paedi-
atric emergency department (ED) reporting a 3-day 
course of periumbilical abdominal pain, accom-
panied by general malaise and nausea, without 
vomiting. The patient was obese, with history of 
familial type IV hyperlipidemia (Fredrickson’s) 
phenotype and acute recurrent pancreatitis (ARP) 
(five episodes beginning at age 11 years, having 
undergone multiple abdominal ultrasounds, an 
upper gastrointestinal endoscopy, an abdominal 
CT, a magnetic resonance cholangiopancreatog-
raphy (MRCP), investigation of celiac disease, 
cystic fibrosis, autoimmune diseases and other etio-
logical studies, without identification of the cause). 
Between the acute episodes, nutritional support was 
provided to the patient. Family history was positive 
for obesity (both parents), asthma and celiac disease 
(mother), and type II diabetes, dyslipidemia and 
early cardiovascular disease (maternal family). The 
patient has a healthy older sister.
On examination, the patient had skin pallor, 
tachycardia and pain was elicited on epigastric 
palpation. No fever, jaundice, hepatosplenomegaly 
or active bleeding was observed.
Blood tests were performed and revealed leuco-
cytosis, neutrophilia and elevation of amylase 16 
times the upper limit of normal (ULN) (1750 U/L) 
and lipase 53 times the ULN (11 550 U/L). The 
serum calcium, liver enzymes and bilirubin were 
normal. Total cholesterol (188 mg/dL), LDL choles-
terol (119 mg/dL) and triglycerides (178 mg/dL) 
were slightly elevated. An abdominal ultrasound 
was performed but no clear image of the pancreas 
was obtained because of gas interference. An acute 
recurrence of pancreatitis was diagnosed, and he 
was admitted to the hospital with no oral intake and 
was kept on intravenous hydration and analgesia. 
By the fifth day from admission, clinical improve-
ment and stability were noteworthy so he was 
discharged and scheduled a follow-up appointment 
with a gastroenterologist. Four days after discharge, 
he returned to the same paediatric ED due to recur-
rence of nausea and abdominal pain, associated 
with jaundice and coluria. Analytically, elevation 
of transaminases, GGT and direct bilirubin, with 
a clear decrease of pancreatic enzymes in relation 
to the previous episode. An abdominal ultrasound 
was performed, showing a gallbladder with a 5 mm 
parietal thickening, not distended, with thick bile, 
with no signs of lithiasis and a Wirsung channel 
with 3 mm calibre. The patient was admitted and 
started on intravenous analgesia and hydration. He 
clinically improved and was discharged after 6 days. 
A multidisciplinary meeting was held (paediatrics, 
paediatric and adult gastroenterology, surgery and 
radiology), and it was decided to perform an endo-
scopic ultrasound in the outpatient setting.
inveSTigATionS
An endoscopic ultrasound was performed 1 month 
after discharge and revealed diffuse structural 
abnormalities throughout the pancreas suggestive 
of CP, more evident in the cephalic region, with 
a lobular pattern, bands and hyperechogenic foci, 
and also a small parenchymal calcification in the 
head of the pancreas; the Wirsung showed an irreg-
ular calibre, with a stenosis in the cephalic region 
and marked echogenicity of the wall compatible 
with periductal fibrosis; a pseudocyst (17×14 mm) 
was found adjacent to the body–tail transition of 
the pancreas. Biopsies showed mild non-specific 
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Figure 1 Pancreatogram showing distortion of the Wirsung with a 
major cephalic stricture, body dilatation and minor strictures of the tail. 
Intraductal lithiasis can be noted.
Figure 2 Fluoroscopic image of the Wirsung showing a 10Fr stent in 
place from the head to the tail of the pancreas.
Figure 3 Wirsungography showing a marked radiological 
improvement after five sessions of endotherapy.
activity and focal intestinal metaplasia and foveolar hyperplasia, 
consistent with reactive gastropathy.
An endoscopic retrograde cholangiopancreatography (ERCP) 
performed 3 months after discharge confirmed features sugges-
tive of CP with multiple Wirsung stenoses, conditioning dilata-
tion and eventual intraductal lithiasis (figure 1).
In the genetic study, no recognised pathogenic variants were 
identified in the genes analysed. A variant was identified in the 
CFTR gene c.2991G>C (p.Leu997Phe).
diFFeRenTiAl diAgnoSiS
Following the INternational Study Group of Pediatric Pancre-
atitis: In search for a cuRE (INSPPIRE) criteria, this is a case of 
CP since the patient has pancreatic duct abnormalities together 
with some periods of consistent abdominal pain and lipase or 
amylase elevation.
Despite being a known risk factor for CP, the hypertriglycer-
idemia in this case does not seem to be the main reason since 
during the acute episodes, the patient usually has normal to 
slightly elevated triglycerides and LDL cholesterol levels. Accord-
ingly to this hypothesis, a genetic study was run and identified a 
variant in one of the genes whose mutations are associated with 
a higher risk of CP.
Even though the interpretation of pathogenesis of this CFTR 
variant is still conflicting (clinical significance uncertain or 
probably pathogenic), bioinformatically it is predicted to be 
deleterious.
We hypothesised that the pancreatic duct stenoses were 
probably the result of a cicatricial process due to the various 
exacerbations of ARP, considering that such alterations were 
not noticed in previous ultrasounds and MRCP’s. In this case, 
CP was the result of sequelae changes in the Wirsung duct 
resulting from recurrent acute pancreatitis (AP), which in 
this case has a multifactorial aetiology with a genetic predis-
position associated with risk factors such as obesity and 
hypertriglyceridemia.
TReATMenT
The patient underwent five sessions of therapeutic ERCPs 
between May and November with placement of an increasing 
number of plastic stents after dilation with a balloon of the 
pancreatic stenosis. During the ERCP procedures, the patient 
was submitted to pancreatoscopy which helped to confirm 
the presence of small intraductal stones which were removed 
by a dormia basket. Furthemore, the pancreatoscope allowed 
successful placement of a guidewire across the tail strictures 
(figures 2–6).
The patient was also started on pancreatin 150 mg 2id (lunch 
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Figure 4 Image of pancreatoscopy of the pancreatic head where a 
stricture and new vascularisation due to chronic inflammation can be 
noted.
Figure 5 Fluoroscopic image of a pancreatoscope in the Wirsung 
allowing the placement of a guidewire under direct visualisation.
Figure 6 Image of pancreatoscopy of the tail, in which a stone and 
correct placement of the guidewire can be seen.
oUTCoMe And Follow-Up
The patient improved clinically after the therapeutic interven-
tions, being currently without nausea and without the general 
malaise that he felt for several years sometimes on a daily basis.
During the last procedure, there was a clear improvement of 
the cephalic stenoses, still with stenosis in the middle portion of 
the body and a closed stenosis in the body–tail transition, uncon-
strained by the wire. A new ERCP has been scheduled within 4 
months and these interventions are planned to be stopped after 
15 months of endoscopic treatment.
He maintains the usual follow-up with the general paedi-
atrician and paediatric gastroenterology, and is expected to 
progressively transit to adult gastroenterology in the coming 
years, in order to ensure clinical stability in the future.
diSCUSSion
This patient had the first episode of AP at age 11 years. After 
multiple acute bouts, with symptom-free periods between them, 
the diagnosis of ARP was made. By the sixth episode, with 
Wirsung’s duct irreversible changes on endoscopic ultrasound, 
the diagnosis of CP was presumed.
Despite the increasing incidence (or increased awareness) of 
AP in paediatric age,1 2 there is still limited literature regarding 
ARP and CP in children.3 CP remains an uncommon diagnosis 
in this age group, and there is no specific epidemiology avail-
able in paediatrics, despite two studies estimating low-incidence 
rates ranging from below 0.5/100 000 person-years in people 
younger than 20 years old to 0.5/100 000 person-years in chil-
dren and young adults between 0 and 34 years old. In the second 
mentioned group, it has been estimated a prevalence of 10.3 per 
100 000 people.4 5 Major risk factors identified for adult ARP 
and CP are rare in children, so data on the factors that predis-
pose to progression from AP to ARP and CP in children was 
missing.
The INSPPIRE Consortium defined the concepts of AP, ARP 
and CP. The diagnosis of ARP requires the occurrence of two 
episodes of AP, in the absence of irreversible pancreatic struc-
tural changes, with a diseased-free period between the episodes. 
AP is defined by the presence of at least two of the following: 
characteristic abdominal pain; imaging consistent with AP; or 
lipase or amylase levels greater than three times the ULN. The 
diagnosis of CP requires the presence of irreversible, structural 
changes in the pancreas such as diffuse or focal destruction, 
sclerosis, pancreatic duct abnormalities/obstruction with at 
least one of the following: some periods of consistent abdom-
inal pain or lipase or amylase levels greater than three times the 
ULN; exocrine pancreatic insufficiency; or endocrine pancreatic 
insufficiency.3
During the episodes of AP, the patient went through multiple 
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of celiac disease, cystic fibrosis, autoimmune diseases and other, 
all excluding non-genetic risk factors. After the sixth episode, he 
undergone an endoscopic ultrasound and an ERCP that revealed 
pancreatic structural changes, specifically encompassing the 
Wirsung duct and a genetic test was performed revealing a CFTR 
genetic variant.
The INSPPIRE group developed consensus relatively to the 
causal evaluation of ARP and CP. Accordingly, initial evaluation 
of ARP should include AST, ALT, GGT, total bilirubin, fasting 
lipids and total serum calcium. Patients with ARP also should 
have MRCP imaging of the pancreas. The search for a genetic 
cause of CP should include a sweat chloride test and mutation 
analysis of the genes mentioned above.6 MRCP should be used 
as the imaging method of choice, but if the likelihood of thera-
peutic intervention is high, ERCP is the best option.7
Recently, using INSPPIRE Consortium database, several risk 
factors were identified. The most commonly identified for chil-
dren with CP were pancreatitis-predisposing genetic mutations 
(PRSS1—present in more than a half; SPINK1; CFTR; CTRC; 
CPA1). Other risk factors, in descending order of importance, 
include obstructive, toxic/metabolic, autoimmune causes.8 9
CP has an important negative impact on physical and mental 
quality of life.10 Children with severe abdominal pain, multiple 
ED visits, hospitalisations and consequently, missed days of 
school, experience an extreme disruption of normal childhood 
and education. Pain exacerbation and persistency also may lead 
to malnutrition, social deprivation, depression, analgesic depen-
dence and other adverse effects.8 Over time, children with CP 
can develop exocrine pancreatic insufficiency and pancreato-
genic diabetes mellitus.11
In this case, once the diagnosis of CP was established, succes-
sive therapeutic ERCP were planned and executed by an expe-
rienced adult gastroenterologist. The patient was also started on 
pancreatic enzyme replacement therapy (PERT) with pancreatin 
and nutritional support. Throughout the acute episodes the 
treatment was supportive, comprising intravenous hydration 
and analgesia.
For treating painful uncomplicated CP, the European Society 
of Gastrointestinal Endoscopy recommends ERCP as the first-
line interventional option.12 In children, there is no single 
therapy that showed efficacy in stopping progression from 
ARP to CP.9 The main goal of medical management is to treat 
the complications of disease and to alleviate pain (acetamin-
ophen and hydrocodone). Therapeutic ERCP is frequently 
utilised in children with CP and may offer benefit in selected 
cases, specifically if ductal obstruction is present.13 It proved 
to be a safe therapeutic option for pancreatic disorders in 
children when performed at centres with expertise.14 When 
all medical and endoscopic therapies fail to alleviate the pain 
and burden of CP, surgical interventions like cholecystectomy 
and total pancreatectomy or islet cell autotransplantation are 
considered.9 15 PERT is indicated to correct exocrine pancre-
atic insufficiency and malnutrition in CP. Nutritional support 
must be provided.16
Subjects with a CFTR variant have increased risk of recurrent 
AP and CP, which is associate with a significantly increased risk 
of pancreatic cancer but also male infertility and chronic sinusitis 
with minimal lung disease. The mortality rate compared with 
the general population is significantly increased in patients who 
develop pancreatic cancer, but does not appear to be increased 
in patients without pancreatic cancer.17
In the setting of a genetic mutation associated with heredi-
tary pancreatitis, there are no clearly established methods of 
preventing development of disease, and so no family screening 
is indicated unless they develop symptoms. However, close rela-
tives should be counselled to avoid environmental risk factors.17
patient’s perspective
Before the illness manifests itself, although it was some years 
ago, I remember feeling good and having a normal life. During 
hospitalisations and at the time of diagnosis, I remember 
suffering, of feeling exhausted and of not feeling well. 
Hospitalisations were always boring. After the ERCP’s I feel much 
better, I still do not like being hospitalised to perform these 
procedures, but I hope not to suffer so much in the future.
learning points
 ► The episodes of acute recurrent pancreatitis may be 
responsible for the development of chronic pancreatitis 
(CP), since successive sudden events contribute to the 
development of irreversible ductal lesions, particularly 
stenoses, in the pancreatic canals, which fit the definition of 
CP making it important to reassess the clinical situation after 
each recurrence.
 ► CP is a rare diagnosis in childhood, and so it is necessary to 
recognise the lack of experience that paediatric specialists 
have in this area and to recognise the benefits of bringing 
together a multidisciplinary team including adult physicians 
in order to approach the patient.
 ► In addition to reducing the risk of life-threatening 
exacerbations, successful treatment of CP allows the patient 
to have a significant improvement in life quality, alleviating 
the daily symptoms that may have been present for years.
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